> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Fast-Track for Adicet Systemic Sclerosis Drug
- URL: https://www.fdaweb.com/fast-track-for-adicet-systemic-sclerosis-drug/
- Published: 2025-02-27T12:00:00.000Z
- Updated: 2026-09-14T14:54:10.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158739

FDA has granted fast-track designation for Adicet Bio’s ADI-001 for the potential treatment of adults with systemic sclerosis. ADT-001 is described as an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy targeting CD20 to treat autoimmune diseases. FDA has granted it fast-track designation for treating relapsed/refractory Class 3 or 4 lupus nephritis, systemic lupus erythematosus with extrarenal development, and systemic sclerosis.